| Biomarker ID | 519 |
| PMID | 20303520 |
| Year | 2010 |
| Biomarker | EGFR [SNP rs884419] |
| Biomarker Basis | Mutation Based |
| Biomolecule | Mutation |
| Source | Tissue |
| Subjects | Humans |
| Regulation | AG And GG Phenotypes associated with decreased risk of recurrence |
| Odds Ratio/Hazard Ratio/Relative Risk | HR: [A/G Phenotype: 0.094 (95% CI: 0.021–0.413); G/G Phenotype: 0.130 (95% CI: 0.037–0.463)] |
| Effect on Pathways | Pathways Include:- Bladder cancer, PI3K events in ERBB2 signaling, Post-translational regulation of adherens junction stability and disassembly, Agrin in postsynaptic differentiation, Alpha-6 beta-1 and alpha-6 beta-4 integrin signaling |
| Experiment | Biochemical recurrence Vs No recurrence |
| Type of Biomarker | Prognostic |
| Cohort | 212 patients who underwent radical prosteactomy were taken for this study, out of which 168 experienced no recurrence and 44 experienced recurrence. |
| Senstivity | NA |
| Specificity | NA |
| AUC | NA |
| Accuracy | NA |
| Level Of Significance | A/G Phenotype: p= 0.0018; G/G Phenotype: p = 0.0016 |
| Method Used | PCR |
| Clinical | No |
| Remarks | NA |
| Clinical Trial Number | NA |
| Degree Of Validity | Not validated on independent patient dataset |
| Technical Name | EGFR |